Venus Remedies continues to strengthen its global presence with new market authorizations across international markets

Venus believes in the philosophy of making healthcare and even the top medicines available for one and all. Hence, it is committed to cutting down the costs of expensive medication to make it accessible & affordable to the general public.

Venus Remedies achieves the EU GMP renewal from Infarmed, underscoring its precision-driven manufacturing practices. This achievement boosts its advancement in Europe, paving the way for wider market integration and competitive edge throughout the region.

At Venus Remedies, we believe every new approval is more than just a milestone—it is a step closer to saving lives. Recently, we achieved several important global approvals that bring us closer to patients in need across different parts of the world. These approvals show our growing presence in international markets and reflect the trust placed in our medicines.

Driven by innovation and a commitment to elevate global quality standards, Venus Remedies continues to break the barriers in global healthcare by securing key market authorizations.

This helps the company stay aligned with its strategy as it enters new markets, upholding its quality standards and contributing to the improvement of healthcare services in new regions. 

Our team at Venus Remedies is working persistently to achieve its goal of global expansion, which is reflected in its products approvals in new markets like:

Enoxaparin 60 mg PFS Approval in UgandaWe are delighted to have successfully secured marketing authorization for Enoxaparin 60 mg pre-filled syringe (PFS) in Uganda.

Enoxaparin is an anticoagulant used for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis (DVT), pulmonary embolism, and certain types of acute coronary syndrome.

BW HealthcareWorld has featured an expert article by Mr. Saransh Chaudhary, President – Global Critical Care at Venus Remedies and CEO of VMRC, on why metallo-β-lactamase (MBL) inhibitors are crucial in India’s fight against deadly superbugs. The piece underscores the role of innovation and collaboration in tackling antimicrobial resistance.

Venus Remedies and West Pharmaceutical Packaging @westatwork Kriti Kotian, Marketing Specialist at West Pharmaceutical Packaging India

Resistance

Plastic waste may be doing more than harming the environment—it may be accelerating antibiotic resistance. 

The article featured in Outlook Planet breaks down this critical connection.

Highlighting the futuristic approach, this article by Mr. Saransh Chaudhary (CEO Venus Medicine Research Centre, Strategic Board Advisor, and President, Global Critical Care at Venus Remedies) shows the commitment of Venus Remedies to health, sustainability, and scientific leadership.

Join Venus Remedies and Venus Pharma GmbH at CPhI Milan 2024, from October 8th to 10th, in Hall 14, Meeting Rooms G52 & G54.

Rooted in operational consistency and regulatory excellence, Venus Remedies was honored by the Ethiopian Pharmaceutical Supply Service for exemplary contract fulfillment.

A look at this recognition reflects the sustained trust placed in us by international procurement agencies and healthcare systems, acknowledging our ability to deliver essential pharmaceutical formulations on time, in full, and in accordance with stringent global quality standards.

Venus Pharma GmbH is committed to the fight against cancer through itsadvanced range of Anticancer Injectables. Our products are designed to provide effective treatment options that address the unique needsof cancer patients. With a focus on precision, safety, and innovation, our injectables are developed using state-of-the-art technologies and rigorous quality standards. We aim to enhance patient outcomes and improve quality of life through therapies that target cancer at its core while minimizing adverse effects.

We’re proud to share that expert insights from Mr. Saransh Chaudhary, President – Global Critical Care & CEO – VMRC,  have been featured in BioSpectrum India, showcasing his expert views on the rapidly evolving GLP-1 drug market. As the Indian pharmaceutical industry braces for a major shift with the patent expiry of drugs like Semaglutide by March 2026, Mr. Saransh highlighted the critical opportunity this creates for Indian companies.

Venus Remedies Global Presence -96+ countries

We’re proud to announce our participation at CPHI 2025 in Frankfurt, giving us a platform to showcase pioneering innovations driving a greener, healthier tomorrow. Join us from October 28–30 as we explore how sustainability and science can transform global healthcare.

Venus Remedies: A Global Pharma Force with Presence in 100 Countries and 800+ Marketing Authorizations

Marketing Authorization For Bendamustine In Saudi Arabia strengthens our oncology portfolio in the GCC (Gulf Cooperation Council) and reinforces the commitment to delivering high-quality, technology-intensive cancer therapies across global markets.

 Andrijana Pekovic speaks on her experience as the Manager of International Business, reflecting on her journey at Venus Remedies and the exciting markets she leads across Europe. 

She shares key takeaways from CPHI Milan, how she navigates market complexities, and her bold strategic priorities for 2025. From challenges to new growth opportunities, Andrijana offers fresh insights into Venus Remedies’ expanding global footprint. Don’t miss this engaging conversation on growth, leadership, and international success.  https://www.youtube.com/watch?v=Ir9q8KJgQQU&list=PPSV&t=60s

“At Venus, we believe in science with conscience. Joining the UN Global Compact is a natural extension of our values—where access, ethics, and excellence intersect. This move not only amplifies our global credibility but also places us on the frontlines of change, where innovation must meet responsibility. We see this as a deep commitment to our global partners, to every healthcare system we serve, and to the planet we all share.”
— Ms. Aditi K. Chaudhary, President International Business, Venus Remedies Limited.

Venus Meropenem is revolutionizing the fight against serious bacterial infections. With its broad-spectrum action, it effectively targets conditions like pneumonia and urinary tract infections, providing healthcare professionals with a reliable solution. This innovative antibiotic exemplifies the advancements in medical treatment, ensuring better outcomes for patients facing complex infections.

Venus Remedies is proud to join United Nations Global Compact. Our commitment to the United Nations Global Compact is to embed #TenPrinciples on human rights, labour, environment, and anti-corruption into all our business operations. We look forward to driving meaningful impact through our dedication to global sustainability!
United Nations Global Compact

Venus Remedies Limited is delighted to announce the successful registration of our Unit-2 in Baddi and Venus Pharma GmbH from Kuwait, alongside obtaining Marketing Authorizations (MAs) for Carboplatin 450 MG/45 ML. These achievements mark significant milestones in our ongoing commitment to expanding our global footprint and enhancing our pharmaceutical capabilities.

We're glad to announce the renewal of our GMP certification from Ukraine’s SMDC for our manufacturing facility. Covering cephalosporin, carbapenem, and oncology injectables, this certification strengthens our position in Ukraine and other 32 PIC/S countries. It reinforces our commitment to global quality standards and supports growth across the Asia-CIS region. With rising demand for generics and oncology care, we’re set to expand our reach and deliver high-quality therapies to more patients worldwide.

Venus Remedies Featured in The Week for Groundbreaking Organ-on-a-Chip ResearchWe are proud to share that The Week has published an exclusive feature on Organ-on-a-Chip (OoAC) technology, incorporating valuable insights from Mr. Saransh Chaudhary, President – Global Critical Care, Venus Remedies Ltd., and CEO, Venus Medicine Research Centre (VMRC).https://www.theweek.in/news/health/2025/03/19/what-is-organ-on-a-chip-ooac-technology-new-method-to-aid-in-drug-testing-development.html

We are proud to share that Venus Remedies Limited has officially joined the UN Global Compact—the world’s largest corporate sustainability initiative dedicated to upholding the principles of Human Rights, Labor, Environment, and Anti-Corruption.

Join us as Mr. Harmit Singh shares insights into his role at Venus Pharma GmbH and discusses the unique opportunities and challenges in the global markets he oversees. From representing Venus at CPHI Milan to achieving goals under the Passion Premier League, Mr. Singh provides a personal and professional perspective on the journey so far and strategies for future growth. Don’t miss his message to our audience and his thoughts on the exciting opportunities ahead for Venus Remedies.   https://www.youtube.com/watch?v=7GGZdKyAjpg&t=67s                             

Venus Remedies’ novel polymyxin B formulation, VRP-034, has been granted QIDP status by the US FDA—a major breakthrough in combating antimicrobial resistance. Developed with our proprietary Renal Guard technology, VRP-034 reduces nephrotoxicity by up to 70% while maintaining efficacy against drug-resistant infections.

What an incredible final day at CPhI 2024! Venus Remedies wrapped up this amazing event with innovative showcases and powerful conversations with industry leaders. Thank you to everyone who joined us on this journey! Swipe to catch day 3 highlights!

Pharma major Venus Remedies Limited has recently made significant progress in its global expansion by obtaining marketing approvals (MAs) for a wide range of drugs in different countries. We’re excited to share that Carboplatin and Carbol have been approved in Morocco, along with Bortezomib, Gemcitabine, Cefepime, and Oxaliplatin in the Philippines. In addition, we have received approvals for Meropenem in Hong Kong, Ceftriaxone in Mauritania, Methotrexate in Saudi Arabia, Imipenem/Cilastatin in Slovenia, Docetaxel in Portugal, and Ronem in El Salvador.

Our efforts are well recognitioned by global regulatory authorities.Venus's passion for quality is reflected in its ability to align its organization-wide operations to global standards enabling it to secure global and national endorsements – its manufacturing facilities have thus far obtained more than 20 gmp approvals.

Venus Remedies is thrilled to announce a major achievement: our pre-filled syringe (PFS) manufacturing unit in Baddi has been awarded the prestigious PIC/S GMP certification by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA). This is the first time our PFS facility has received accreditation under the Pharmaceutical Inspection Co-operation Scheme (PIC/S), marking an important step in our journey to bring world-class healthcare solutions to new markets.

Venus' Product List for CPHI 2025

Venus Remedies is thrilled to announce a significant achievement in its ongoing mission to enhance cancer care with innovative solutions. The company's German subsidiary, Venus Pharma GmbH, has secured market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion, marking a remarkable milestone for the organization.

Innovation. Excellence. Global Impact.

This October, Venus Remedies is stepping onto the global stage at CPhI Frankfurt 2025 to showcase how our science, dedication, and vision are shaping the future of healthcare.

From cutting-edge R&D breakthroughs to an expanding worldwide footprint, we continue to drive progress in critical care, oncology, and anti-infectives with a strong focus on safety, quality, and accessibility. Our commitment to excellence ensures that every product we create reaches patients with the trust and reliability they deserve.

At Booth 3.0F6, we’ll be sharing:

Our growing injectable portfolio designed for evolving healthcare needs

Advanced CDMO services that bring flexibility and scale to global partners

Breakthrough AMR-focused strategies to fight the rise of antimicrobial resistance

Insights into how we are building a stronger, more sustainable pharma future
L...

Venus Remedies has taken a significant step in combating Antimicrobial Resistance (AMR) by securing exclusive licensing rights for MET-X, an innovative anti-bacterial drug from UK-based Infex Therapeutics. This landmark partnership will enable Venus Remedies to develop, gain regulatory approvals, and commercialize MET-X in India, reinforcing its commitment to tackling drug-resistant infections.

Generic Products: We are commited to cut down the cost of expensive medicines to make them availaible to masses

Venus Remedies Limited, a global leader in the pharmaceutical industry, has achieved significant milestones by securing two prestigious tenders from globally renowned organizations—UNICEF and the Pan American Health Organization (PAHO). These wins mark a pivotal moment in the company's journey towards enhancing healthcare access and outcomes worldwide.

Venus Pharma GmbH is committed to expanding its product pipeline, market reach, and strategic partnerships. Our investments in biopharmaceutical research, digital health solutions, and precision medicine ensure that we remain at the forefront of industry advancements.

Pharma major Venus Remedies on Tuesday said it has secured renewal of European Good Manufacturing Practices (EU-GMP) certification by Infarmed, the National Authority of Medicines and Health Products in Portugal. This renewal is applicable to the company's manufacturing facility for Cephalosporin, Carbapenem, and Oncology (Liquid and Lyophilized Injectable) formulations, a statement said.

Venus Remedies Prodcut List for CPHI

Ms. Olha Mykhalchuk, Assistant Manager at Venus Pharma GmbH, International Marketing-Business Development-CIS, as she dives into her journey in the pharmaceutical industry. From her current role and past experiences to the challenges she faces during client interactions, Ms. Olha shares insights into her career path in pharmaceutical industry.

Product Catalogues

Meet Ms. Andrijana Pekovic, Manager – International Businesses at Venus Pharma GmbH, as she shares her insights on global expansion, meaningful collaborations,

BW HealthcareWorld has featured an expert article by Mr. Saransh Chaudhary, President – Global Critical Care at Venus Remedies and CEO of VMRC, on why metallo-β

When the global pharma community gathers at CPhI, it’s not only about science or business deals. It’s also about the people who make progress possible.

Venus Remedies is honored to receive the marketing authorization for Bendamustine in Saudi Arabia, one of the strictly regulated global pharmaceutical markets.

Meet Andres Villamiza, leading the LATAM region for Venus Remedies Limited. He’s all set to connect, collaborate, and shape the future of pharma innovation.

We look forward to creating meaningful global partnerships as Ms. Olha Mykhalchuk, shares key insights to builds connections, and explore global opportunities.

Venus Remedies expands its global footprint as the Philippines grants marketing approval for Sugammadex, a breakthrough anesthetic reversal drug.

Venus Remedies achieves EU GMP renewal from Infarmed, underscoring its precision-driven manufacturing practices. This achievement boosts its advancements.

We are proud to announce our latest membership with the United Nations Global Compact (UNGC), the world's largest corporate sustainability platform.

In a significant boost to our global manufacturing credentials, we have successfully renewed our Good Manufacturing Practices (GMP) certification from Ukraine’s

We are proud to share a landmark achievement in our journey at Venus Remedies Limited—one that shines a global spotlight on India’s role in tackling one of the

Exciting times ahead at CPHI Frankfurt 2025! Meet Andres Villamiza, leading the LATAM region for Venus Remedies Limited, with over 25 years of experience.

Elevating Global Healthcare Through Multiple Key Authorizations

Venus Remedies has been recognized among the Top 10 Injectable Manufacturers in India, reflecting its long-standing focus on quality, safety, and complex injectable therapies.

Venus Remedies has earned its place in this segment over more than three decades. The company has built its reputation through sterile manufacturing practices, regulatory-driven systems, and a consistent focus on patient safety. This recognition is not recent or incidental—comes from years of infrastructure development, process refinement, and working with products where there is no margin for error. Injectables, often used in critical care, demand the highest level of accuracy and control.

Venus Remedies continues to expand its reach with 10 new Market Authorizations across multiple international markets. These include Enoxaparin 20 mg/0.2 ml for El Salvador, Carboplatin Pontus 150 mg/15 ml and 450 mg/45 ml for Netherlands, Docetaxel Injection USP 80 mg/2 ml for Ethiopia, Meropenem 500 mg and Vincristine 1 mg/1 ml for Chile, Imipenem/Cilastatin 500 mg for Serbia, Vancomycin 1 gm for Iraq and Methotrexate Venus 1000 mg/10 ml for Saudi Arabia.

Additionally we take pride in Strategic Milestones, such as the registration of Carboplatin in Georgia and the first-time approval of Midazolam 15 mg/3 ml, further strengthen our presence in critical care and emerging market!

Expanding Horizons in Global Therapeutics. Venus Remedies proudly marks another milestone with new Marketing Authorizations across diverse international markets, reinforcing our vision of improving global access to advanced healthcare solutions. Each new authorization strengthens our presence in global markets and reflects our unwavering dedication to delivering quality, innovation, and care to patients worldwide.

Venus Remedies has achieved  new market authorizations across key international markets.These approvals include marketing approvals for key oncology and critical care products including Docetaxel in Nigeria, Meropenem in Panama, Bleomycin in Morocco, Irinotecan and Cefuroxime in Vietnam, Dexmedetomidine in Oman, and Fluorouracil in El Salvador.These regulatory achievements reaffirm our commitment to expanding access to high-quality, globally compliant therapies and advancing healthcare across diverse markets worldwide.

From visionary leadership to new international marketing authorizations, Venus Remedies continues to build a stronger global presence delivering trusted oncology and critical care therapies across diverse markets. With responsible growth and regulatory excellence, we remain committed to improving patient outcomes worldwide.

enus Remedies continues to build a stronger global presence delivering trusted oncology and critical care therapies across diverse markets. With responsible growth and regulatory excellence, we remain committed to improving patient outcomes worldwide.

At Venus Remedies, we continue to expand our presence with a focus on safe and effective therapies. Each approval reflects our commitment to quality, compliance, and patient needs.As we strengthen our footprint across regulated and emerging markets, every step brings us closer to bridging gaps in healthcare—delivering consistency where it matters most.

We are excited to meet you at CPhI Frankfurt 2025!

At Venus Remedies, our journey is defined by innovation, partnership, and commitment — reaching over 100+ countries with 1081 market authorizations and a single purpose: bringing safe, reliable medicines to the world, one step at a time.

As we continue to uphold global manufacturing standards, champion sustainable practices, and strengthen our WHO, PAHU, EU GMP, and UNGC accreditations, we invite you to join us in shaping the future of pharma — together.

Let’s meet and exchange ideas that inspire progress and build partnerships that drive global healthcare forward.

Access to quality healthcare should never depend on geography – but it still does. 

Millions of people around the world struggle to access treatments that could save lives or improve their quality of care. Factors like cost, limited infrastructure, and geographic barriers mean that breakthroughs in healthcare don’t always reach those who need them most.

Sometimes, even the most critical care treatments do not reach the patients who need them the most. CPHI 2025 bring together scientists, manufacturers, and healthcare leaders to deal with these challenges. 

CPHI bridges this difference by providing a platform to share solutions, explore partnerships, and drive innovations that make healthcare more reliable and accessible.

With a focus on quality, safety, and patient access, we at Venus Remedies ensure that life-saving treatments are accessible to people worldwide.

CPHI provides a global stage for our vision, driven b...

The ESG Framework at Venus Remedies
At Venus Remedies, sustainability practices follow a clear framework. Our sustainability initiatives are based on three pillars—Environmental, Social, and Governance (ESG) factors are taken into account for every action and work process.

Our ESG approach is not a short-term goal but a long-term initiative. From eco-friendly production to responsible waste management, empowering communities and maintaining transparency, we remain committed to the larger vision of sustainable healthcare with:

CPHI’s Role in Driving Sustainable Pharma
Experts, researchers, and companies in healthcare from around the globe gather at CPHI to share knowledge and explore new possibilities. This event offers a platform for collaboration with experts in the healthcare industry. It also opens more opportunities for partnerships and innovations that can change the course of the healthcare industry for the better.

Venus, a research-centric pharmaceutical company in India, engages in and promotes research and innovation as its core of operations. This approach forms the base of VRL and other top pharmaceutical research companies and the best products they offer.

Our Research & Development focuses on providing innovative solutions for unmet medical needs & being a partner of choice for pharma research across the value chain.

Patients are at the core of our thinking, and we make sure that our efforts do not end with developing a new product, medicine, or therapy but extend beyond to provide a holistic solution to the patients. Our innovation program focuses on some of the most demanding health care challenges, including AMR and oncology. We are working relentlessly towards our aim of possibilities for patients so as to reduce their suffering by providing better solutions for unmet medical needs.

A

Exciting times ahead at CPHI Frankfurt 2025!Meet Andres Villamiza, leading the LATAM region for Venus Remedies Limited, with over 25 years of experience in the pharmaceutical industry. This year, he’s all set to connect, collaborate, and shape the future of pharma innovation.  Join us at Stand 3.0F6 from October 28th–30th at Messe, Frankfurt. Let’s exchange insights, explore groundbreaking solutions, and build impactful partnerships. Let’s drive the future of pharmaceuticals together!Click on the link to know more: https://bitly.cx/ScZAZ

Strategic Focus Unleashing Growth Through Strategic Alliances Open for in-licensing, contract manufacturing, and product development across Europe. Specialization: Critical Care Injectables with focus on antibiotics and oncology molecules.

Quality Assured: Product Testing and Release Batch release facility for pharmaceutical formulations. Product testing at multiple levels in in-house laboratories ensures reliabil...

We are Indian pharmaceutical company with global footprints in more than 100 countries.